Surgical Science Sweden AB
OTC:SUSRF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Surgical Science Sweden AB
OTC:SUSRF
|
SE |
|
SAP SE
F:SAP
|
DE |
|
Pro-Dex Inc
NASDAQ:PDEX
|
US |
|
Aker Carbon Capture ASA
OSE:ACC
|
NO |
|
H
|
HIVE Blockchain Technologies Ltd
F:HBF
|
CA |
|
Oxford Square Capital Corp
NASDAQ:OXSQ
|
US |
|
I
|
Innoprise Plantations Bhd
KLSE:INNO
|
MY |
|
Bleuacacia Ltd
NASDAQ:BLEU
|
US |
|
Pegasus Hava Tasimaciligi AS
IST:PGSUS.E
|
TR |
|
S
|
Shinsegae Engineering & Construction Inc
KRX:034300
|
KR |
Wall Street
Price Targets
SUSRF Price Targets Summary
Surgical Science Sweden AB
According to Wall Street analysts, the average 1-year price target for SUSRF is 5.54 USD with a low forecast of 3.54 USD and a high forecast of 8.09 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SUSRF's stock price target?
Price Target
5.54
USD
According to Wall Street analysts, the average 1-year price target for SUSRF is 5.54 USD with a low forecast of 3.54 USD and a high forecast of 8.09 USD.
What is Surgical Science Sweden AB's Revenue forecast?
Projected CAGR
12%
For the last 10 years the compound annual growth rate for Surgical Science Sweden AB's revenue is 36%. The projected CAGR for the next 3 years is 12%.
What is Surgical Science Sweden AB's Operating Income forecast?
Projected CAGR
63%
For the last 10 years the compound annual growth rate for Surgical Science Sweden AB's operating income is 44%. The projected CAGR for the next 3 years is 63%.
What is Surgical Science Sweden AB's Net Income forecast?
Projected CAGR
55%
For the last 10 years the compound annual growth rate for Surgical Science Sweden AB's net income is 45%. The projected CAGR for the next 3 years is 55%.
